As both GLP-1 analogues and DPP-4 inhibitors are increasingly used in the management of T2DM (more often in combination therapy with metformin) [17], one important question that may arise is which one of the two drug classes is more favorable as a second-line treatment of T2DM [18], [19]. This evidence concerns the gene GCG and type 2 diabetes mellitus.